SCHEMBL5212424

SCHEMBL5212424

Cc1c(C)c(O)c(C)c(NC(=O)OCc2ccccc2)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
SMN1; SMN2 Q16637 4/20 0.54
MAOA P21397 3/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 3/20 0.49
TSHR P16473 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 1/20 0.49
MGLL Q99685 1/20 0.48
KDM1A O60341 2/20 0.46
MAOB P27338 2/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213739 0.97 NPC1 (0.60) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL5220382 0.93 NPC1 (0.58) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL3028839 0.88 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL28562156 0.84 SMN1; SMN2 (0.60) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL3041603 0.81 NPC1 (0.58) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL26960329 0.79 NPC1 (0.60) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL28564954 0.79 NPC1 (0.64) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL3029059 0.78 NPC1 (0.66) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL28562202 0.78 SMN1; SMN2 (0.58) NPC1RAB9ASMN1; SMN2MAOAPOLB
SCHEMBL7229249 0.77 NPC1 (0.65) NPC1RAB9ASMN1; SMN2MAOAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1228367-B1 AMINOPHENOXYACETAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF ASUBIO PHARMA CO LTD (JP) 2007-09-26 EP disclosed
US-20060178401-A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof DAIICHI ASUBIO PHARMA CO., LTD. 2006-08-10 US disclosed
US-7067533-B2 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2006-06-27 US disclosed
US-20030139447-A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof ASUBIO PHARMA CO., LTD. (JP) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139447-A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof SCN10A, CAMK2A, CAMK2B NPC1 3518/4885RAB9A 3105/4885SMN1; SMN2 1127/4885
US-20060178401-A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof NR0B1, NR0B2, NR4A1 NPC1 2348/4885RAB9A 4060/4885SMN1; SMN2 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.